Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	39.31	70.17	31.16
Short-Term Investments	281.35	77.31	-
Cash & Short-Term Investments	320.66	147.48	31.16
Cash Growth	929.11%	373.31%	-
Prepaid Expenses	0.9	3.31	0.11
Restricted Cash	0.11	0.09	-
Total Current Assets	325.94	150.87	31.27
Property, Plant & Equipment	5.02	4	0.34
Long-Term Deferred Charges	-	0.3	-
Other Long-Term Assets	0.19	0.25	-
Total Assets	331.14	155.42	31.6
Accounts Payable	1.32	2.5	1.45
Accrued Expenses	5.06	5.63	0.21
Current Portion of Leases	0.72	0.67	-
Total Current Liabilities	7.1	8.8	1.66
Long-Term Debt	-	4.2	10.44
Long-Term Leases	0.93	1.48	-
Total Liabilities	8.03	14.48	12.1
Common Stock	0.04	0.04	0.03
Additional Paid-In Capital	426.44	19.76	0.56
Retained Earnings	-103.77	-45.44	-10.65
Comprehensive Income & Other	0.4	0	-
Total Common Equity	323.11	-25.63	-10.06
Shareholders' Equity	323.11	140.94	19.51
Total Liabilities & Equity	331.14	155.42	31.6
Total Debt	1.65	6.35	10.44
Net Cash (Debt)	319.01	141.13	20.72
Net Cash Growth	1439.33%	581.01%	-
Net Cash Per Share	25.80	93.73	26.66
Filing Date Shares Outstanding	36.58	4.17	0.78
Total Common Shares Outstanding	36.58	4.17	0.78
Working Capital	318.84	142.07	29.61
Book Value Per Share	8.83	-6.15	-12.95
Tangible Book Value	323.11	-25.63	-10.06
Tangible Book Value Per Share	8.83	-6.15	-12.95
Machinery	3.76	1.76	0.3
Construction In Progress	0.07	0.03	0.06
Leasehold Improvements	0.28	0.26	-

Source: S&P Capital IQ. Standard template. Financial Sources.